IBOV 185,147.15 ▼ 0.02% IPSA 11,315.26 ▼ 1.14% IPC MEX 64,866.61 ▼ 0.87% MERVAL 3,049,121 ▼ 0.29% COLCAP 2,544.56 ▲ 0.40% BVL PERÚ 59,978.22 ▼ 0.31% USD/BRL5.12▼ 0.03% USD/MXN16.90▲ 0.10% USD/CLP933.68— 0.00% USD/COP3,124▼ 1.12% USD/PEN3.35▼ 0.34% USD/ARS1,509▲ 0.01% USD/UYU40.24▲ 1.33% USD/PYG5,947▲ 1.88% USD/BOB12.40▲ 3.56% USD/DOP59.00▲ 0.85% USD/CRC448.67▲ 1.78% USD/GTQ7.63▲ 2.28% USD/HNL26.84▲ 0.28% USD/NIO36.62— 0.00% USD/VES805.37▼ 0.90% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.71▲ 1.02% EUR/BRL5.95▲ 0.91% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 185,147.15 ▼ 0.02% IPSA 11,315.26 ▼ 1.14% IPC MEX 64,866.61 ▼ 0.87% MERVAL 3,049,121 ▼ 0.29% COLCAP 2,544.56 ▲ 0.40% BVL PERÚ 59,978.22 ▼ 0.31% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Sunday, September 6, 2026

Extensive Covid-19 Antibody Tests Could Prevent Second Global Lockdown

By · March 27, 2020 · 4 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – No country yet knows how many of its fellow citizens have actually been infected with the new Sars-CoV-2 – and are hence already immune. As a result, no one can currently project whether the infection rate will immediately rise again following the lifting of the strict lockdowns and other measures restricting contact.

To prevent this – and thus another lockdown that would be catastrophic for the economy and society – so-called antibody tests would need to be started as soon as possible.

To prevent the infection from rising again following the lifting of the strict lockdowns - and thus another lockdown that would be catastrophic for the economy and society - so-called antibody tests would need to be started as soon as possible.
To prevent the infection from rising again antibody testing would need to be started as soon as possible.
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

Testing students and teachers before school opens

Such tests can be used to determine whether a person was infected with the coronavirus. According to the current findings, the person is then immune for at least a few weeks or months. This is because the organism produces antibodies specifically directed against the pathogen.

Experts currently assume that such Sars-CoV-2 antibodies show in the blood between the eighth and eleventh day after the onset of the first symptoms. During the infection, mainly IgM type antibodies are circulating, followed by IgG type antibodies.

Specialized tests for these subtypes can thus be used to determine whether a patient is still in the acute stage of the disease or is already in its post-stage. However, because of the delayed onset of antibody formation after infection, antibody tests are not suitable for detecting an infection. For this purpose, so-called PCR tests are used worldwide, which detect the genetic material of the virus in nasal or throat swabs.

Extensive test programs provide the urgently needed data for a multitude of cases. In order to protect risk groups after a lockdown, hospital staff or staff in old people’s and nursing homes would have to be identified who, thanks to their immune protection, should primarily be used in the care of patients or senior citizens.

This would protect everyone, staff as well as patients and residents, from infections.

Similarly, in the first stage after lockdown, primarily immune staff could be allowed access to companies or schools and kindergartens could be opened where a large number of students and teachers are immune.

Many undetected sars-CoV-2 infections are likely to have occurred and continue to occur in children and adolescents in particular, because in this age group the infection is often mild and therefore goes undetected.

Also the discharge of patients who have the Covid-19 lung disease caused by the virus could become more efficient and safer for the population through antibody tests, as reported by a hospital in Wuhan. The hospital has been using such tests since early March, according to Chinese media reports.

If a patient has no IgM but many IgG antibodies, then it is clear that they have survived the disease and can be discharged, explain the doctors.

In Switzerland and Germany, antibody tests for Sars-CoV-2 are currently only available for research purposes; one is being tested at the University Hospital in Zurich, for instance.
In Switzerland and Germany, antibody tests for Sars-CoV-2 are currently only available for research purposes; one is being tested at the University Hospital in Zurich, for instance.

Numerous tests are being developed worldwide

Singapore has recently launched a major testing program to assess immunity in the general population. In fact, millions of antibody tests would have to be performed in each country for these very extensive screenings. And these would have to be repeated at regular intervals.

Since the production and evaluation of antibody tests is comparatively simple and can be automated, testing a blood sample in mass production costs only a few cents.

Such programs would therefore be much cheaper for each country than the multi-million-dollar aid funds that are currently being set up in many countries.

Because antibody tests are such an important tool, they are currently being developed by a large number of institutions and companies worldwide. China is a pioneer in this field: almost a dozen such tests have already been approved there, some also in the USA.

In Switzerland and Germany, antibody tests for Sars-CoV-2 are currently only available for research purposes; one is being tested at the University Hospital in Zurich, for instance.

However, one problem remains: the antibody tests have been developed so rapidly that nobody knows exactly how reliable they are.

Little has been published about them to date. And the scant available data, such as those from the University of Rotterdam or the Icahn School of Medicine at Mount Sinai in New York, show that although the tests are reliable, they have so far only been tested with the blood of very few Covid-19 patients.

However, for conclusive mass screenings, extensive analyses must prove that a test can detect antibodies against Sars-CoV-2 very precisely, but not those against other coronaviruses (which have been present in the population for years).

Only if the specificity is very high does a screening of the population provide reliable results. In contrast, many false-positive results would massively overestimate the immunity against Sars-CoV-2.

Naturally, antibody tests alone do not prevent new infections. This requires a prudent population that returns to social life with due caution after the social distancing measures have been lifted.

People with symptoms or suspected infection would have to remain isolated and examined with PCR tests.

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.